Ovary Flashcards

(42 cards)

1
Q

Follicular Cyst

A
  • Benign cyst measuring at least 3 cm
  • If < 3 cm, called cystic follicles
  • Lined by an inner layer of granulosa cells
  • Outer layer of theca cells
  • Formed due to abnormal gonadotrophin stimulation
  • Contain clear fluid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Corpus luteum cyst

A
  • Cyst over 3 cm in size
  • Inner layer of luteinized granulosa cells
  • Outer layer of theca cells
  • Corpus luteum is a physiological postovulatory structure formed after the dominant follicle releases the ovum
  • Its main purpose is to secrete estrogen and progesterone and it normally regresses at the end of the cycle
  • Cystic dilation happens when corpus luteum fails to regress and becomes enlarged with fluid / blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hyperreactio luteinalis

A
  • Bilateral, ovarian enlargement due to multiple, luteinized follicle cysts
  • Thin-walled cysts
  • Rare
  • Associated with hydatidiform mole, choriocarcinoma, fetal hydrops due to Rh sensitization and multiple gestations

Micro:
* Follicular cysts with luteinization of theca interna or granulosa cells, edema of theca layer and stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Polycystic ovary disease

A
  • Polycystic ovarian syndrome (PCOS) is a clinicopathologic syndrome comprising polycystic ovaries and characteristic clinical features

Clinical:
* Most common cause of anovulatory infertility
* Grossly enlarged, multicystic ovaries
* May not be enlarged in adolescent patients
* Associated with endometrial hyperplasia and endometrial neoplasia

Micro:
* Increased ovarian size, including thickness of cortical and subcortical stroma
* Thickened collagenized tunica
* Normal numbers of primordial follicles
* Twice the expected number of ripening and atretic follicles
* Multiple cystic follicles (1 - 2 mm) with luteinized theca layer (theca lutein hyperplasia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Endometriosis

A
  • Presence of endometrial tissue outside of endometrium and myometrium, consisting of both endometrial glands and stroma
  • Ectopically located endometrial tissue consisting of at least 2 of the following:
  • endometrial type glands
  • endometrial type stroma or
  • evidence of chronic hemorrhage
  • Endometriosis is associated with
  • Ovarian clear cell carcinoma
  • Endometrioid carcinoma

Molecular:
* ARID1A
* PIK3CA
* KRAS
* PPP2R1A

IHC:
* CD10 immunohistochemistry can be used to confirm the presence of endometrial stroma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Neoplastic Lesions of Ovary

A

Epithelial (~95%)

Type 1
* Low Grade Serous –> KRAS, BRAF
* Endometroid –> KRAS, PIK3CA, PTEN, CTNNB1, ARID1A
* Mucinous –> KRAS, ERBB2, TP53
* Clear Cell –> KRAS, PIK3CA, PTEN, AKT2, ERBB2

Type 2
* High Grade Serous –> TP53, BRCA1/2
* Undifferentiated –> KRAS, HER2

Non-Epithelial (~5%)

  • Germ Cell
  • Ovarian Sarcoma
  • Sex-Cord Stromal
  • Small Cell Carcinoma

Pathogenesis:
* Type 1
Progress from benign tumours through borderline tumours
Give rise to low-grade carcinoma

  • Type 2
    Arise from inclusion cysts/Fallopian tube epithelium
    Via intraepithelial precursors that are often not identified
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Type 1 vs Type 2 Serous Ovarian Cancers

A

Type 1
* Progress from Ovarian low malignant potential (LMP) tumors, also known as borderline epithelial ovarian tumors
* Usually low grade
* RAS pathway frequently mutated
* BRCA wild type
* Generally TP53 wild type
* p16 patchy
* Chromosomally stable
* Frequently platinum insensitive

Type 2
* De novo invasive tumours
* High grade
* RAS wild type
* BRCA dysfunction
* TP53 mutant
* P16 block-positive
* Wide spread DNA copy number change
* Usually platinum sensitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Spectrum of Tubal Epithelial Alterations

A

Serous tubal intraepithelial carcinoma (STIC)

  • Lesion that is limited to the fallopian tube epithelium and a precursor to extrauterine (pelvic) high grade serous carcinoma

Micro:
* Confined to epithelium
* Significant atypia, architectural alterations
* High proliferative index
* Mutant pattern of p53 staining

  • Important precursor lesion to recognize, as it is a criterion for assigning fallopian tube as primary site of high grade tubo-ovarian serous carcinoma irrespective of presence and size of ovarian and peritoneal disease

Terminology:
Various terms used to describe a spectrum of tubal epithelial alterations:

**Secretory cell outgrowths (SCOUTs): **
* Secretory cell expansion with variable ciliation
* Type 1 / tubal differentiation
* Type 2 / endometrioid differentiation
* Wild type p53 staining

p53 signature:
* Histologically normal epithelium (at least 12 cells)
* Mutant pattern p53 staining
* Low proliferation index (MIB1) (typically less than 10%)

**Serous tubal intraepithelial lesion (STIL): **
* Abnormal histology (high N/C but preserved polarity)
* Mutant p53
* Variable MIB1
* STIL is regarded as a lesion of uncertain significance and diagnostic features fall short of STIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Epithelial Ovarian Cancers

A

High Grade Serous Carcinoma
* 70% all carcinomas
* Precursor: STIC (Fallopian Tube Epithelium)
* Syndromes: BRCA1/2, Hereditary breast and ovarian cancer (HBOC)
* Mutations: TP53, BRCA1/2, HRD, Chromosomal instability, Aneuploidy
* Therapies: PARP inhibitors

Low Grade Serous Carcinoma
* < 5% all carcinomas
* Precursor: Serous borderline tumour (Fallopian Tube Epithelium)
* Syndromes: ??
* Mutations: KRAS, BRAF
* Therapies: MEK1/2 inhibitors

Clear Cell Carcinoma
* <10 % all carcinomas
* Precursor: Clear cell borderline tumour (Endometriosis)
* Syndromes: Lynch syndrome
* Mutations: ARID1A, PIK3CA, CTNNB1, PPP2R1A, MSI
* Therapies: Tyrosine Kinase inhibitors

Endometrioid Carcinoma
* <10 % all carcinomas
* Precursor: Endometrioid borderline tumour (Endometriosis)
* Syndromes: Lynch syndrome
* Mutations: PTEN, ARID1A, CTNNB1, PPP2R1A, MSI
* Therapies: mTOR inhibitors

Mucinous Carcinoma
* <5 % all carcinomas
* Precursor: Mucinous borderline tumour (unknown)
* Syndromes: ?
* Mutations: KRAS, HER2 amplification
* Therapies: Trastuzumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Serous Cystadenoma/ Adenofibroma

A
  • Benign
  • Partially or completely cystic lesion
  • Measuring > 1 cm
  • Composed of cells resembling fallopian tube epithelium or
  • Cuboidal nonciliated epithelium resembling ovarian surface epithelium

Micro:
* Usually small, uni to multilocular cysts
* Lined by a single layer of tall, columnar, ciliated cells resembling normal tubal epithelium or
* Cuboidal nonciliated epithelium resembling ovarian surface epithelium
* Stroma contains spindle fibroblasts
* If papillae are present, they are simple

Adenofibromas and cystadenofibromas
* Composed predominantly of fibrous stroma
* Glands and cysts form a minor component
* If < 10% of the total tumor shows epithelial proliferation within the cysts that would qualify as serous borderline tumor –> designated as serous cystadenoma with focal epithelial proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Serous Borderline Tumour

A
  • Low grade epithelial neoplasm
  • Generally younger women with a favorable prognosis when diagnosed at an early stage
  • Nonobligate precursor to low grade serous carcinoma (LGSC)
  • Can give rise to extra-ovarian abdominoperitoneal or lymph node implants
  • Frequently bilateral (up to 33%)
  • If peritoneal implants –> risk of recurrence

Macro:
* Complex cystic lesion
* Some delicate papillary excrescences lining inner surface

Micro:
* Non-invasive
* Epithelial proliferation and atypia
* Floating epithelial tufts
* Arbourising papillae –> lined by pseudostratified, cilliated, fallopian tube type epithelium

Molecular:
* KRAS
* BRAF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Implants

A
  • Extraovarian spread is referred to as implants
  • Two types:

1) Non-invasive –> Epithelial type, Desmoplastic type
2) Invasive –> LG serous Carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

BRCA

A
  • BRCA 1 and 2 –> very high risk for HGSC
  • Often get prophylactic salpingoophorectomy
  • BRCA-related cancers have ‘SET’ –> Solid, pseudo-Endometrioid, and Transitional morphology
  • Lots of tumour-infiltrating lymphocytes
  • Most originate in fallopian tube –> tubal origin until proven otherwise
  • Normal tube –> p53 mutation –> STIC –> invasive HGSC –> spreads to ovary
  • Rx –> cytotoxic chemotherapy and debulking staging surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mucinous cystadenoma and adenofibroma

A
  • Benign
  • Mucinous neoplasm
  • Cysts and glands lined by gastrointestinal or Müllerian type mucinous epithelium
  • Lacks architectural complexity or cytologic atypia
  • May arise from mature teratoma or Brenner tumour

Macro:
* Usually unilateral (95%)
* Smooth or bosselated surface

Cystadenoma:
* Uni or multilocular cyst with variably sized smooth walled locules
* Filled with dense, viscous, sticky, gelatinous material
* No solid areas or papillary excrescences
* Mean size 10 cm, rarely > 30 cm

Adenofibroma:
* Usually smaller
* Predominantly white and solid with variable amounts of small cysts

Molecular:
* KRAS mutations in 68% of cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mucinous borderline tumor

A
  • Noninvasive
  • Mucinous neoplasm with complex architecture and gastrointestinal type differentiation

Macro:
* > 90% of the tumors are unilateral
* Mean size: 22 cm; some tumors can measure as large as 50 cm
* Cysts are multiloculated with mucinous contents
* Smooth external surface
* Solid areas and necrosis may be present

Micro:
* Complex architecture with tufting and villus formation
* Epithelium resembles low grade dysplasia of the intestine
* Goblet cells, neuroendocrine cells and occasional Paneth cells present
* Neoplastic cells have hyperchromasia, crowding, stratification and mitotic activity
* Glands with luminal mucin

IHC:
CK7
CK20 (variable)
CDX2 (variable) [the extent of expression of CK7 is greater than that of CK20 or CDX2] (Am J Surg Pathol 2006;30:1130)
PAX8 (focal)
SATB2 is positive in a small subset of cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Mucinous carcinoma

A
  • Unilateral
  • Large, complex solid and cystic masses without surface involvement
  • 77% of ovarian mucinous carcinomas are metastases
  • 23% are ovarian primaries
  • Of the ovarian primaries, most arise in a benign or borderline tumor

Two types of invasion -
* Expansile
* Infiltrative –> destructive

  • Expansile tumors are usually stage I and behave “benign”
  • Infiltrative tumors may demonstrate malignant behavior and cause death even if stage I

Grading:
Not standardized and does not predict prognosis independent of stage.

  • Grade 1-no solid areas
  • Grade 2-up to 50% solid foci
  • Grade 3-more than 50% solid foci
  • Severe nuclear atypia can increase raise grade I or II carcinomas by one grade

Molecular:
* KRAS mutations frequent

IHC:
CEA
CK7
CK20
CA125 (weak)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ovarian mucinous tumours - Primary vs Mets

A

Primary
* Unilateral&raquo_space;> Bilateral
* Often >10cm
* Usually expansile growth pattern
* No LVI
* No surface involvement
* No hilar involvement
* May have associated teratomas, Brenner tumours, mural nodules
* Rarely associated with pseudomyxoma peritoneii
* SATB usually negative, SMADA4 retained

Metastasis
* Bilateral > Unilateral
* Rarely >10cm
* Usually infiltrative growth pattern
* Often LVI
* Often surface involvement + acellular mucin
* Hilar involvement often present
* Associated ovarian pathology usually absent
* SATB2 usually positive in GI mets, SMADA4 may be lost

Common sites of involvement
* Appendix
* Pancreas
* Colon
* Gallbladder
* Stomach
* Cervix

18
Q

Mural Nodules

A
  • Grossly circumscribed nodules
  • Most associated with primary ovarian mucinous neoplasms (less frequently other ovarian tumor types)
  • May be microscopically invasive but still separate / distinct from the associated mucinous tumor
  • Associated mucinous tumor may be benign, borderline or malignant
  • Reactive and malignant can be hard to tell apart

Types:
* Reactive (sarcoma-like)
* Benign neoplastic (leiomyomatous)
* Malignant (anaplastic carcinoma, sarcoma, carcinosarcoma)

19
Q

Endometrioid carcinoma of the Ovary

A
  • Ovarian carcinoma resembling endometrioid adenocarcinoma of the endometrium
  • Usually low grade and diagnosed at early stages
  • May be associated with endometriosis and adenofibroma
  • Stage is the most important prognostic factor

Macro:
* Usually unilateral; only 5% bilateral
* Cystic with solid component and areas of hemorrhage

Micro:
* Most common –> confluent (back to back) glands
* Stromal invasion usually by expansion
* Rarely, destructive stromal invasion can be observed
* Squamous metaplasia (morules or keratin pearls) can be seen

Histologic grading:
* Same as for endometrial endometrioid adenocarcinoma

  • FIGO grade 1: less than 5% solid component
  • FIGO grade 2: 6 - 50% solid component
  • FIGO grade 3: more than 50% solid component

IHC:
* Keratin cocktails
* EMA
* CK7
* PAX8 (15% negative)
* ER and PR
* p53: wild / normal type expression (most tumors), high grade endometrioid cancers might demonstrate mutational pattern
* Mismatch repair protein deficiency has been reported in up to 23% of tumors

20
Q

Clear cell carcinoma of the Ovary

A
  • Malignant epithelial tumor
  • Usually unilateral
  • Solid to cystic
  • May be associated with endometriosis or Lynch syndrome
  • Stage is the most important prognostic factor

Micro:
* Clear, eosinophilic or hobnail cells
* 3 classic growth patterns, frequently admixed but 1 pattern may predominate

Papillary:
* Most frequent (70%)
* Usually small, round, simple, nonbranching papillae with fibrous / hyalinized, edematous / myxoid or empty (open tumor rings) stromal cores
* Lined by 1 - 2 layers of cuboidal, flattened or hobnail cells
* Micropapillary tufts may be seen

Tubulocystic:
* Frequent (65%)
* Variably sized tubules and cysts, with or without intraluminal dense eosinophilic secretions and outpouchings
* Lined by a single layer of hobnail, cuboidal or flattened cells
* Often associated with an adenofibromatous background

Solid:
* Least common (62%)
* Diffuse sheets or nested clusters of polyhedral cells separated by delicate septa exhibiting clear to eosinophilic cytoplasm

Molecular:
* ARID1A
* PIK3CA

IHC:
* CK7 +
* HNF-1B +
* Napsin A +
* PAS + –> glycogen rich cytoplasm
* ER/PR -
* WT1-

21
Q

Brenner tumors

A
  • Tumor composed of transitional / urothelial-like epithelium, typically embedded in fibromatous stroma
  • Benign, borderline and malignant variants are recognized, based on the growth pattern and cytological features of the epithelial cells
  • Cell of origin of Brenner tumors is controversial; they may arise from Walthard rests
  • No atypia
  • No increased mitotic activity

Micro:

Benign Brenner tumor:
* Nests of bland transitional epithelium present within fibromatous stroma

Borderline Brenner tumor:
* Papillary architecture with papillae covered by multilayered transitional epithelium
* There is variable but usually low grade cytological atypia

Malignant Brenner tumor:
* Stromal invasion by carcinoma with transitional cell features
* Associated with a benign or borderline Brenner tumor

IHC:
* p63
* GATA3
* CK7
* Uroplakin
* Thrombomodulin
* EMA
* CEA

22
Q

Walthard cell nests

A
  • Nests, plaques or cysts (with eosinophilic luminal material)
  • Metaplastic transitional epithelium involving the serosal surface of fallopian tube, mesosalpinx and mesovarium
  • Benign common incidental finding
  • Bland transitional type epithelium forming small nests / cysts

Micro:
* Small solid nests or cysts of transitional type epithelium
* Relatively uniform nuclei with irregular borders and nuclear grooves, located beneath the serosa of tubal / paratubal / paraovarian tissue
* Cystic lesions may have eosinophilic luminal secretions
* Rare or no mitotic figures

IHC:
* p63
* GATA3
* CK7

Negative:
* PAX8
* CK20
* Uroplakin
* SALL4

Pathogenesis:

Early events:
* Activating PIK3CA mutations (27%)
* CDKN2A loss (55%)

Two different pathways, Late events:
* FGFR3 alterations (45%)
* MDM2/TP53 alterations (46%)

23
Q

Ovarian Cancer Genetics

A

Sporadic:
* 85-90%

Hereditary:
* 10-15%
* 80-90% –> BRCA1 and 2, RAD51c and RAD51D –> Hereditary Breast and Ovarian Cancer Syndrome
* Further syndromes –> Lynch, Li-Fraumeni, Cowden, Gorlin, Peutz-Jeghers

Hereditary Breast and Ovarian Cancer Syndrome:
* BRCA1
* BRCA2
* Breast, Ovary, Melanoma, Prostate, Pancreatic Ca

Hereditary Breast and Ovarian Cancer Syndrome:
* RAD51C
* RAD51D
* BRIP1
* Ovary Ca

Lynch Syndrome:
* MLH1
* MSH2
* MSH6
* PMS2
* EPCAM
* Uterine, Colon, Ovary, Pancreatic, Gastric, Small Bowel, CNS, Renal, Sebaceous

Cowden Syndrome:
* PTEN
* Breast, Uterine, Thyroid, Colon, Renal, Sebaceous

Li-Fraumeni:
* p53
* Sarcomas, Breast, Adrenal, Brain, Lung, Endometrial

Peutz-Jegers:
* STK11
* GI, Breast, Ovarian, Sex cord stromal, Uterine, Cervical

Gorlin-Goltz Syndrome:
* Autosomal dominant
* PTCH1 –> Chromosome 9
* Dental/Ossesum anomalies
* Cutaneous anomalies –> BCC, dermal cysts
* Opthalmic –> Hypertelorism strabismus
* Neurological –> retardationm, calcification of falx cerebri
* Sexual anomalies –> Hypogonadism, Ovarian tumour

24
Q

Ovarian Sex Cord Stromal Tumours

A

Pure Stromal Tumours:
* Fibroma
* Thecoma
* Steroid Cell
* Leydig Cell
* Sclerosing Stromal

Pure Sex Cord Tumours:
* Adult Granulosa Cell
* Juvenile Granulosa Cell
* Sex Cord Tumour with Annular Tubules

Mixed Sex Cord-Stromal Tumours:
* Sertoli-Leydig Cell

Hormone Producing Ovarian Tumours:

Oestrogen Producing:
* Granulosa Cell
* Thecoma

Androgen Producing:
* Steroid Cell
* Sertoli-Leydig Cell
* Leydig Cell

IHC:
* Either +ve or -ve for CK
* Almost always EMA -ve
* +ve EMA suggests epithelial mimic
* Inhibin –> Relatively specific marker
* Calretinin –> More sensitive, less specific
* CD56 –> cytoplasmic and membranous
* WT1 –> Nuclear
* SF-1

25
Fibroma
* Benign stromal tumor * Fibroblastic cells * Variably collagenous stroma **Macro:** * Well circumscribed mass with smooth, lobulated surface * Firm, chalky, solid, white to yellow-white to tan-yellow cut surface that may be whorled * Frequent oedema resulting in softer consistency * Mean size 6 cm * Usually unilateral (< 10% bilateral) * Cystic degeneration in ~25% of cases * Calcifications in ~10% of cases **Micro:** * Spindled or ovoid cells * Abundant collagen * Bland nuclear features **Variants:** * Cellular Fibroma --> Cellular with scant collagen, mild atypia, increased mitoses * Mitotically Active Cellular Fibroma * Minor Sex Cord Elements **IHC:** WT1 SF1 FOXL2 (no mutation) Inhibin: 50% of cases, often focal or weak Vimentin CD56 ER/PR SMA Reticulin: differentiates fibroma (individual pericellular reticulin staining pattern) from diffuse type of adult granulosa cell tumor (nested reticulin staining pattern) **Syndromes:** * Gorlin Syndrome --> if young and bilateral * Meig's Syndrome --> Fibroma + Ascites + Pleural Effusion (resolve after removal of ovarian tumour)
26
Thecoma
* Ovarian stromal neoplasm * Almost always benign * Usually occurs in postmenopausal women who present with uterine bleeding **Macro:** * Usually unilateral * Most are < 5 cm * Solid, yellow and lobulated or white with focal yellow areas * Occasional cystic change and hemorrhage * Necrosis is rare **Micro:** * Sheets of uniform cells * Pale greyish-pink cytoplasm * Cytologically bland * Reticulin surrounds individual cells **IHC:** Inhibin Calretinin Reticulin stain shows a pericellular pattern SF1 FOXL2 WT1 CD56 Vimentin Oil red O in lipid rich cells
27
Steroid cell tumor
* Ovarian stromal tumor composed of steroid cells with malignant potential * Mostly unilateral * Half of cases have androgenic manifestations --> hirsuitism **Macro:** * Wide size range * Unilateral (95%) * Solid, well circumscribed, occasionally lobulated * Sections from yellow-orange (lipid rich) to red-brown (lipid poor) to dark brown-black (abundant lipochrome pigment) * Occasionally with necrosis, hemorrhage and cystic degeneration **Micro:** * Architectural pattern: diffuse (most common) but occasionally in nests, cords, pseudoglandular and follicle-like arrangements * Stroma: usually sparse (85%) but may be fibrotic or hyalinized, rarely edematous or myxoid * Polygonal to rounded tumor cells with distinct cell borders, central nuclei and moderate to abundant cytoplasm * Tumor cell cytoplasm: eosinophilic and granular (lipid poor) to vacuolated and spongy (lipid rich); * Lipochrome pigment present (40%) **IHC:** Inhibin Calretinin SF1 MelanA Androgen receptor (64%) Vimentin (75%) CD99
28
Leydig cell tumor of the Ovary
* Benign steroid cell tumor composed of polygonal cells with abundant eosinophilic cytoplasm and Reinke crystals * Postmenopausal occurrence * Predominantly located in the ovarian hilus, close to nerve fibers * Often lobulated or nodular growth * Reinke cytoplasmic crystals present * Secretes androgens --> masculisation **Micro:** * Unencapsulated neoplasms * Smooth or irregular borders located in the hilus, next to nonmedullary nerve fibers * Round to polygonal cells with abundant eosinophilic or vacuolated cytoplasm and round nuclei with small nucleoli * Reinke crystals: eosinophilic, cytoplasmic rod, rectangular or hexagonal crystals * Lipochrome pigment is common * May have cytoplasmic pseudoinclusions or bizarre nuclear atypia **IHC:** Inhibin Calretinin MelanA MITF SF1 CD99
29
Adult granulosa cell tumor
* Low grade indolent malignant neoplasm originating from granulosa cells of the ovarian follicles * 20-30% chance of local recurrence, 5-20 years after diagnosis * Secretes Oestrogen --> Menorrhagia, PMB, Amenorrhea **Micro:** * Scant, pale architecture * Grooved nuclei * Varied architecture --> Sheet-like, trabecular, ribbon-like, microfollicullar * Call-Exner bodies filled with pink secretions * Frequent mitoses **Molecular:** FOXL2 point mutations **IHC:** * FOXL2 immunostain is a sensitive (80%) and specific (99%) marker for sex cord stromal tumors (SCST) * SF1: most sensitive marker for this as well as most common sex cord stromal tumors * Inhibin A: more specific marker * Calretinin * **Reticulin: shows lack of pericellular staining and highlights nests or large groups of granulosa cells and vessels, helps differentiate diffuse pattern from fibroma / thecoma ** * Low molecular weight cytokeratin (CAM5.2, AE1 / AE3): 30 - 60%, usually dot-like or globoid perinuclear pattern * S100: 50% * CD99: 70% * Vimentin, WT1, CD56 and SMA
30
Juvenile granulosa cell tumor
* Sex cord stromal tumor composed of primitive appearing granulosa cells with follicular and solid growth patterns * Sex cord stromal tumor with primitive granulosa cell differentiation * Solid and follicular growth * Almost always occurs in patients younger than 30 years * Lacks the FOXL2 somatic mutation seen in adult granulosa cell tumor * Usually stage IA and associated with a favorable prognosis **Macro:** * Usually unilateral with a smooth surface * Mean size 12.5 cm * Multiloculated, cystic and solid tumor with yellow-white solid areas * May have hemorrhage and necrosis **Micro:** * Cells are round, abundant oesinophilic cytoplasm * NO GROOVES * Macrofollicular * Basophillic secretions * Frequent mitoses **Molecular:** NO FOXL2 mutations **IHC:** Inhibin Calretinin SF1 WT1 FOXL2 BRG1 (SMARCA4) (retained)
31
Sex cord tumor with annular tubules
* Distinctive variant of sex cord stromal tumor * Characterized by sharply circumscribed nests composed of ring-like tubules that encircle basement membrane-like material * 2 types: sporadic and syndromic, the latter is associated with Peutz-Jeghers syndrome **Macro:** **Nonsyndromic tumors:** * Unilateral masses ranging in size from several millimeters to 3 cm * Solid, tan to yellow * Cysts may be seen and occasionally may predominate **Syndromic tumors:** * Bilateral and multifocal lesions * Often microscopic; may not be grossly visible * Gritty texture may be noted if there is a mass **Micro:** * Syndromic and nonsyndromic tumors have similar morphology * Variably size round nests of sharply delineated simple and complex tubules * Tubules contain basement membrane-like material, which may also be present around the tubules * Cells are columnar with clear cytoplasm * Antipodal nuclei. Tumors associated with Peutz-Jeghers syndrome: * Calcifications within the tubules may be seen * May be associated with endocervical gastric type adenocarcinoma (adenoma malignum) Nonsyndromic / sporadic tumors: * May focally transition to granulosa or Sertoli cell morphology * Cytologic atypia and mitotic activity may rarely be seen * May be hyalinized **IHC:** Calretinin WT1 Inhibin SF1 FOXL2 CD56
32
Sertoli-Leydig cell tumor
* Accounts for < 0.5% of all ovarian neoplasms * Common in young patients --> mean age of 25 * Composed of sex cord (Sertoli cells) and stromal (Leydig cells) elements * May occur sporadically or in patients with DICER1 syndrome **3 molecular subtypes:** **DICER1 mutant:** * Younger age * Moderately / poorly differentiated * Retiform or heterologous elements **FOXL2 c.402C>G (p.Cys134Trp) mutant:** * Postmenopausal patients * Moderately / poorly differentiated * No retiform or heterologous elements **DICER1 / FOXL2 wildtype:** * Intermediate age * No retiform or heterologous elements * Including all well differentiated tumors **Micro:** * Well differentiated * Moderately differentiated * Poorly differentiated * Histologic grade and subtype correlates with clinical behaviour * Sertoli-Leydig cell tumour with heterologous elements (Rhabdomyoblasts) * Sertoli-Leydig cell tumour with retiform variant * Intestinal metaplasia may be seen. **IHC:** * General sex cord proteins, such as inhibin, calretinin, SF1, FOXL2, CD56, WT1 and CD99 * Vimentin and pancytokeratin * MelanA / MART1 in Leydig cells * CK20 and CDX2 in heterologous intestinal type mucinous epithelium * AFP, arginase and HepPar1 in hepatoid elements * Reticulin histochemical staining may be helpful in differentiating Sertoli-Leydig cell tumor (completely absent or nested pattern) from fibromas and thecomas (individual pericellular reticulin network) * Absence of reticulin staining is not specific for Sertoli-Leydig cell tumors, as adult granulosa cell tumors and epithelial ovarian tumors also show the same staining pattern
33
DICER1 Syndrome
* Varients of protein encoded by DICER1 gene on chromosome 14 * DICER1 syndrome is a rare, inherited genetic disorder that increases the risk of developing tumors * Autosomal dominant **Tumors** * **Pleuropulmonary blastoma:** A cystic lung tumor that may transform into an invasive tumor if not diagnosed and treated early. * **Multinodular goiter (MNG):** A non-cancerous thyroid condition in which there are multiple nodules throughout the thyroid. * **Cystic nephroma:** A non-cancerous kidney tumor. * **Sertoli-Leydig cell tumor: **An ovarian tumor that is more common in females with a faulty DICER1 gene. **Other conditions** * Goiter (an enlarged thyroid) * Polyps in the colon may also occur. Inheritance
34
Sclerosing stromal tumor
* Benign stromal tumor * Pseudolobular appearance resulting from alternating cellular and hypocellular areas **Macro:** * Typically unilateral * Well circumscribed * White-yellow variegated solid mass * Often edema and cysts * Hemorrhage, calcifications and rarely necrosis may be seen **Micro:** * Moderately cellular pseudo-lobuiles with numerous thin-walled vessels. * Cellular areas --> fibroblasts and lip-laden vaculolated cells * Separated by oedematous connmective tissue or dense collagenous stroma * Sclerosis is present within the nodules * Rare mitoses **Molecular:** GLI2 rearrangements in 81% FHL2 is the most common gene partner **IHC:** Inhibin calretinin FOXL2 CD10 smooth muscle actin Diffuse TFE3 expression in a subset of tumors
35
Small cell carcinoma of the Ovary
1. Pulmonary Type 2. Hypercalcaemic Type --> More common **Hypercalcaemic Type** * Young women * Unilateral * Associated with paraneoplastic hypercalcaemia * Undifferentiated tumour * Diffuse growth of small, monotonous cells with scant cytoplasm * Often focal macro follicle-like spaces * Often a component of larger cells with more cytoplasm * Very aggressive **IHC:** Diffuse WT1 Focal CK and EMA Loss of nuclear **SMARCA4 / BRG1** expression **Pulmonary Type** * Must exclude a metastasis * Older women * Often bilateral with extra-ovarian spread * Diffuse growth of smnall cells with scant cytoplasm * Salt and Pepper chromatin, and moulding * Losts of mitoses and apoptotic bodies * Poor prognosis
36
Germ Cell Tumours
* Dysgerminoma * Yoke Sac Tumours * Embryonal Carcinoma * Choriocarcinoma * Teratoma * Struma Ovarii
37
Dysgerminoma
* Malignant primitive germ cell tumor with no specific type of differentiation * Most common germ cell tumour (Female seminoma) * Most common in children and young women * Usually unilateral * Elevated serum LDH * Rarely elevated hCG * Excellent prognosis with chemotherapy **Micro:** * Sheets or nests of uniform cells with clear or eosinophilic cytoplasm and distinct cell membranes * Nuclei are rounded, often with angulated edges * Tumor often separated by fibrous septae containing cytotoxic T cells and epithelioid histiocytes that can extend into tumor **Molecular:** Majority have isochrome 12p ckit mutations **IHC:** SALL4 OCT3/4 --> nuclear positivity D2-40 CD117 PLAP
38
Yolk sac tumor
* Most common before the age of 30 * Usually unilateral ovarian mass with predilection for right ovary * Usually occurs as a pure form or rarely as a component of a mixed germ cell tumor * Numerous morphologic patterns, with the hallmark Schiller-Duval bodies * Elevated serum alpha fetoprotein (AFP) * Usually favorable clinical outcomes due to chemosensitivity * Pure hepatoid and glandular intestinal types associated with poorer prognosis **Molecular:** Chromosome 12 abnormalities, usually isochromosome 12p **Micro:** * Multiple patterns * Most common --> reticular/microcystic * Schiller-Duval bodies --> A central blood vessel surrounded by layers of tumor cells, contained in a cystic space **IHC:** SALL4: marker of primitive germ cell differentiation AFP: highly specific but 60% sensitive, often patchy / focal and weak Glypican 3: less specific but stronger expression PLAP HNF1β Pancytokeratin GATA3: positive in reticular / microcystic, papillary and polyvesicular vitelline patterns but not in the glandular pattern HepPar1: positive in glandular and hepatoid patterns CEA, albumin: positive in hepatoid pattern TTF1: positive in foregut / respiratory pattern CDX2: positive in glandular intestinal type pattern Villin: positive in reticular / microcystic and glandular intestinal type patterns
39
Embryonal Carcinoma
* Primitive appearing ovarian tumor that is histologically similar to embryonal carcinoma of the testis * Often a component in a malignant mixed germ cell tumor of the ovary; the pure form is exceedingly rare * May show serum elevation of AFP or βhCG with positive pregnancy test * Aggressive but respond to chemotherapy **Micro:** * Similar to embryonal carcinoma of the testis * Often mixed with other malignant germ cell tumor components * Sheets and nests of large, primitive pleomorphic cells with abundant cytoplasm * Round nuclei with coarse membranes, at least 1 prominent nucleolus and brisk mitotic activity * Occasional papillae and gland morphology * Syncytiotrophoblast-like tumor cells are seen (hCG+) around sheets of tumor cells or within stroma * Hyaline globules, similar to yolk sac tumor, may also be present * Glandular pattern may mimic endometrial carcinoma or glandular morphology of a yolk sac tumor **Molecular:** Isochrome 12p **IHC:** SALL4, OCT 3/4 and SOX2 nuclear positivity CD30 membranous positivity OCT 3/4 more sensitive than CD30 but can also be expressed in dysgerminoma AE1 / AE3 βhCG positive in syncytiotrophoblastic cells AFP may be expressed in both tumor cells and hyaline globules CD30 expression might decrease after chemotherapy
40
Choriocarcinoma
* Rare primary ovarian tumor; < 1% of primitive ovarian germ cell tumors * May develop from: * Ovarian pregnancy (gestational choriocarcinoma), * Germ cell tumor (pure or mixed, non-gestational choriocarcinoma) or * Surface epithelial tumor with choriocarcinomatous differentiation * Markedly elevated bHCG --> monitoring helps predict reecurrence and response to therapy * Non-gestational choriocarcinomas are difficult to treat --> unresponsive to chemotherapy * Mets to lungs, liver, bone, and viscera are common at diagnosis **Micro:** * Composed of cytotrophoblast, intermediate trophopblast and multinucleated syncytiotrophoblast around periphery of blood channels **IHC:** Cytokeratin, CD10, human placental lactogen, EMA Syncytiotrophoblasts are hCG+
41
Teratoma
* Composed of tissues form 2-3 germs layers * Often and cystic and unilateral * Common elements --> skin with adnexal structures, cartilage, GI, Brain **Types:** * Mature (benign) * Immature (malignant) * Teratoma with malignant transformations * Monodermal teratomas --> struma ovarii --> mostly/all thyroid * Carcinoid --> resemble well-differentiated NET tumours of GI tract **Mature Teratoma** * Mature tissue representing at least 2 embryonic layers * If malignant transformation (rare), prognosis is related to the type of malignancy * Most common ovarian tumor (20% of all ovarian tumors, 95% of all ovarian germ cell tumors) * Reproductive age * 10% bilateral **Immature Teratoma** * Malignant germ cell tumor of the ovary composed of cells from the 3 germ layers and containing variable amounts of mature and immature tissue * Affects mostly young females < 20 years old * Grossly solid ovarian tumor mass with necrosis and hemorrhage on cut sections * Grading is based on the amount of immature neuroepithelium * Can have associated nodal or peritoneal gliomatosis (presence of mature neural tissue), which increases risk of recurrence * Grading and stage are the most important factors for prognosis and prognosis is greatly improved after chemotherapy **Struma Ovarii** * Ovarian teratoma either composed predominantly or exclusively of benign thyroid tissue or with any amount of malignant thyroid tissue * Most common thyroid malignancy to occur in struma ovarii is papillary thyroid carcinoma, followed by follicular carcinoma **Macro:** * Typically unilateral * <10cm * Smooth surfaced * Solid, brown or green-brown * Fibrous septa * Fluid-filled cysts containing brown-green gelatinous fluid **Micro:** * Mature thyroid tissue or adenoma with small and large follicles lined by a layer of columnar, cuboidal, or flattened epithelium * May show changes similar to thyroid gland --> hyperplasia or thyroiditis **IHC:** * PAS higfhlights colloid * Thyroglobulin highlights thyroglobulin in the struma component **Monodermal teratomas: carcinoid tumour:** * Primary carcinoid rumours of the ovary are associated with other teratomatous elements in 85-90% cases * Most commonly insular carcinoid * 30 to 80 years * Carcinoid syndrome --> flushing, diarrhoea, abdo cramping, cardiac involvement * Elevated urinary 5-hydroxyindole acetic acid **Micro:** * Insular carcinoid resembles midgut carcinoid --> discrete groups of small uniform cells separated by fibrous stroma. * Nuclei with coarse chromatin * Rare mitoses * Associated with other teratomatous components **IHC:** * Chromogranin * Synaptophysin * NSE positive
42
Germ Cell Tumour Markers
**PLAP** * All **SALL4** * All **LIN28** * All **OCT3/4** * Dysgerminoma * Embyronal Carcinoma **SOX2** * Embryonal Carcinoma * Immature Teratoma **D2-40** * Dysgerminoma * Choriocarcinoma **CD30** * Embyronal Carcinoma **AFP** * Yolk Sac * Immature Teratoma **Glypican-3** * Yolk Sac * Immature Teratoma * Choriocarcinoma **B-hCG** * Choriocarcinoma